

INDEX

ACKNOWLEDGEMENTS.....	III
ABSTRACT.....	IV
RESUMEN	VI
RESUM.....	VIII
LIST OF ABBREVIATIONS.....	X
1. INTRODUCTION	1
1.1. ASSOCIATION BETWEEN CANCER AND THROMBOSIS	1
1.1.1. Cancer-related factors	3
1.1.1.1. Primary site of cancer	3
1.1.1.2. Stage of cancer.....	3
1.1.1.3. Time span from cancer diagnosis to thrombotic event	3
1.1.2. Treatment-related factors	4
1.1.2.1. Cancer therapy	4
1.1.2.2. Erythropoiesis-stimulating agents and transfusions.....	4
1.1.2.3. Surgery and hospitalization.....	4
1.1.2.4. Central venous catheters	4
1.1.3. Patient-related factors	5
1.1.3.1. Comorbidities.....	5
1.1.3.2. Prior history of venous thromboembolism.....	5
1.1.3.3. Prothrombotic mutations.....	5
1.1.3.4. Age, sex and race	5
1.1.3.5. Performance status and mobility.....	6
1.2. RISK SCORES FORCANCER-ASSOCIATED THROMBOSIS.....	6
1.3. BLADDER CANCER	10
1.4. PANCREATIC CANCER	13
1.5. INTRACRANIAL TUMORS: GLIOMA AND MENINGIOMA.....	13
1.6. NOVEL BIOMARKERS OF CANCER-ASSOCIATED THROMBOSIS.....	14
1.6.1. microRNAs	14
1.6.2. Neutrophil activation markers.....	19
2. HYPOTHESIS	24
3. OBJETIVES.....	25
4. CHAPTER 1: Identification of miR-29c-3p as a Robust Normalizer for Urine microRNA Studies in Bladder Cancer.....	26

5. CHAPTER 2: Validation of a microRNA profile in urine liquid biopsy with diagnostic and stratification value for bladder cancer subtypes, usage through the open app BladderMiRaCan	50
6. CHAPTER 3: microRNAs and Neutrophil Activation Markers Predict Venous Thrombosis in Pancreatic Ductal Adenocarcinoma and Distal Extrahepatic Cholangiocarcinoma	78
7. CHAPTER 4: microRNAs and Markers of Neutrophil Activation as Predictors of Early Incidental Post-Surgical Pulmonary Embolism in Patients with Intracranial Tumors	108
8. DISCUSSION.....	141
8.1. NEW NON-INVASIVE BIOMARKERS FOR THE DIAGNOSIS AND STRATIFICATION OF BC PATIENTS	142
8.2. NEW BIOMARKERS FOR CANCER-ASSOCIATED THROMBOSIS	144
8.2.1. Pancreatic cancer	144
8.2.2. Intracranial tumors.....	145
9. CONCLUSIONS	146
10. REFERENCES.....	148